Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05532566
Other study ID # T525-STD-043
Secondary ID 2020-005388-30
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date January 2, 2023
Est. completion date April 30, 2024

Study information

Verified date August 2022
Source Inmunotek S.L.
Contact Miguel Casanovas
Phone 912908942
Email mcasanovas@inmunotek.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this study is to determine the biological activity of Quercus illex and Quercus robur allergen extracts in histamine equivalent prick (HEP) units, in order to be used as in-house reference preparation (IHRP).


Description:

The trial will consist of a single visit, in which the following procedures will be carried out: - Demographic data. - Clinical history. - Inclusion/exclusion criteria. - General examination. - Performance of prick-tests (3 concentrations of Quercus ilex allergenic extract, 3 concentrations of Quercus robur allergenic extract, positive control and negative control). - Obtaining a blood sample from the patient to create a pool of sera for the "in vitro" standardization of the allergenic extract. This pool of sera is necessary for the characterization of the Company's standard. Each serum sample will be stored in a tube that will be labeled with the subject number and frozen. These serum samples will remain in the freezer until the study is completed. When the study is completed, they will be transported to the laboratory, where all sera will be pooled. This "pool" of sera will be used to perform the complementary in vitro standardization tests. These include ELISA for measurement of inhibition against specific IgE, etc. These serum samples are not destroyed. They are pooled together to form a pool that will be used, as described in the previous paragraph, in all the in vitro tests necessary to standardize and characterize this extract and produce its corresponding HIRP (In-house reference preparation), as indicated by the Royal Spanish Pharmacopoeia and the European Pharmacopoeia. This pool of sera is not destroyed, it is used in the in vitro analyses necessary for the standardization of new batches of this allergenic extract. Once the pool has been formed, the tubes containing the original serum samples are destroyed. - Evaluation of adverse events.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 30
Est. completion date April 30, 2024
Est. primary completion date January 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 64 Years
Eligibility Inclusion Criteria: - Subjects must live in a geographical area where allergic problems caused by Quercus ilex and Quercus robur are relevant. - Positive clinical history of inhalant allergy (rhinitis and/or rhinoconjunctivitis and/or asthma) to asthma) to Quercus ilex and Quercus robur. - A positive prick-test (mean papule diameter = 3 mm) with an extract of the same allergen and/or presence of specific IgE against that allergen. - The mean papule area obtained with Histamine dichlorhydrate at 10 mg/mL should be = 7 mm2. - Age: Between 18 and 64 years old. - Subjects must be able to give informed consent. Exclusion Criteria: - Subjects should not be excluded in terms of low or high sensitivity to Quercus ilex and Quercus robur. - Subjects outside the age range. - Subjects who have previously received immunotherapy in the last 5 years for the treatment of asthma or rhinoconjunctivitis for the treatment of asthma or allergic rhinoconjunctivitis induced by allergens that may interfere with Quercus ilex and Quercus robur extracts. - Subjects with significant symptoms of rhinoconjunctivitis and/or bronchial asthma in which the suspension of the systemic antihistamine treatment is contraindicated. - Subjects who have previously presented a severe secondary reaction during the performance of diagnostic skin tests by prick test. - Subjects under treatment with ß-blockers. - Subjects clinically unstable (acute asthma, febrile, etc.). - Subjects with active urticaria lesions, severe active dermographism, severe atopic dermatitis, sunburn, eczema, psoriasis lesions in the area where the prick test is performed (risk of false positives). - Subjects with active viral infection by herpes simplex or herpes varicella zoster in the area where the prick test is performed. - Subjects with any pathology in which the administration of adrenaline is contraindicated (hyperthyroidism, HTA, cardiopathy, etc.). - States of the subject in which he/she cannot offer cooperation and severe psychiatric disorders. - Pregnant women or women at risk of pregnancy and lactating women.

Study Design


Intervention

Other:
Allergenic extract
In each subject a drop of each of the 3 concentrations of both allergenic extracts will be applied in addition to the positive control (histamine) and the negative control. The application will be made in duplicate on the anterior face of the subject's arm. The distance between each application should be approximately 4 cm.

Locations

Country Name City State
Spain Clínica Subiza, centro de asma y alergia Madrid

Sponsors (1)

Lead Sponsor Collaborator
Inmunotek S.L.

Country where clinical trial is conducted

Spain, 

References & Publications (3)

Arntzen FC. Progress in common Nordic Guidelines for the Registration of Allergen Preparations. Arb Paul Ehrlich Inst Georg Speyer Haus Ferdinand Blum Inst Frankf A M. 1983;(78):25-8. — View Citation

Larsen JN, Dreborg S. Standardization of Allergen Extracts. Methods Mol Biol. 2019;2020:63-76. doi: 10.1007/978-1-4939-9591-2_5. — View Citation

Sjöholm I. Standardisation of allergens in Europe. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M. 1997;(91):107-10. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Size of the induced papule on the skin Size of the induced papule on the skin when applying each of the concentrations of the allergenic extracts and the positive (histamine) and negative controls, using the prick test. 15 minutes
Primary Adverse reactions Mild secondary reactions such as pruritus, erythema, local edema, etc. There is a risk, infrequent and exceptional, of systemic reactions, sometimes severe (urticaria, asthma, anaphylactic shock, etc.). 30 minutes
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04058743 - Nickel Sensitivity N/A
Not yet recruiting NCT05649891 - Checklists Resuscitation Emergency Department N/A
Active, not recruiting NCT05605795 - Investigation of Cross-allergies Between Cefazolin and Amoxicillin With Skin Tests and Provocation Test
Recruiting NCT06065137 - Standardised Drug Provocation Testing in Perioperative Hypersensitivity N/A
Completed NCT04510376 - Allergy Potential of Omeza Collagen Matrix in Human Subjects Using the Skin Prick Method N/A
Completed NCT05185479 - Analysis of Adverse Events in Anesthesia Using Artificial Intelligence
Recruiting NCT05185362 - Epidemiology of Pecan Nut Allergy
Completed NCT03489694 - Repeatability and Reproducibility of Skin Test Endpoint Titration
Completed NCT03525496 - Interest of Challenge Tests for Diagnosis of Immediate Hypersensitivity Against Iodinated Contrast Agents
Completed NCT03942692 - What is the Allergy Follow-up for Children After Anaphylactic Reaction? AFCAR : Allergy Follow-up for Children After Anaphylactic Reaction
Enrolling by invitation NCT05670756 - Preoperative Survey to Evaluate Patient Allergy
Recruiting NCT05462444 - Development of Personalized Balanced Nutrition Concept Through an IT Platform
Not yet recruiting NCT05284253 - Is There an Allergy to Pure Metallic Gold Microparticles? N/A
Completed NCT03157505 - Efficacy and Safety of Birch Pollen Immunotherapy in Local Allergic Rhinitis Phase 3
Completed NCT01436617 - Assessing the Value of a Dosage of Anti-cetuximab in the Therapeutic Management of Patients With Colon Cancer or Upper Aero-digestive Tract and Candidates for Treatment With Cetuximab Phase 2
Not yet recruiting NCT05533385 - Juniperus Oxycedrus and Cupressus Arizonica Allergen Extracts Standardisation. N/A
Recruiting NCT06011603 - Prineo Sensitivity Dressing Study Phase 4
Completed NCT04761822 - COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations Phase 2
Recruiting NCT05367531 - Assessment of Injectable Medication Platforms N/A